search
Back to results

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

Primary Purpose

Pain, Pain, Postoperative

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
cryoSPHERE Ablation
Bupivacaine
Sponsored by
The Methodist Hospital Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring pain management, pulmonary surgical procedures, robotic surgical procedures, pneumonectomy, nerve block, neuroma, analgesics, opioid, bupivacaine, length of stay, drug tolerance

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients 18-90 years of age
  • Diagnosis requiring robotic-assisted thoracoscopic surgery
  • 3. Daily opioid use for at least 30 days consecutively at any point during the last 12 months prior to surgery.
  • Agreement and consent to comply with all aspects of the study protocol and data collection, including follow-up contact.

Exclusion Criteria:

  • Previous major surgery at the operative site (thoracotomy)
  • Allergy to aluminum
  • Allergy to plastics
  • Allergy to bupivacaine
  • Shingles disease
  • Demyelinating illnesses
  • Involvement with other interventional studies

Sites / Locations

  • Houston Methodist Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation

Historical Controls

Arm Description

The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.

A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.

Outcomes

Primary Outcome Measures

Opioid Use Within 24 Hours After Chest Tube Removal
Opioid use measured as the daily dose of milligram morphine equivalents (MME)

Secondary Outcome Measures

Total Emergent Adverse Effects (TEAE)
Morbidity, defined as total emergent adverse effects (TEAE) for the experimental group vs. control
Length of Hospital Stay
Time spent in the hospital from admission for surgery until discharge or death
Mean Cost of Hospital Care
Total cost of billed medical care for the surgery
Number of Readmissions
The number of readmissions to the hospital
Neuroma Formation
The formation of a neuroma around the site of nerve block administration
Pain Score
Patient's perceived pain level on a scale of 1 to 10
PROMIS3a Pain Intensity
Patient's perceived pain level on a scale of 3-15, per PROMIS Pain Intensity Short Form 3a v1.0
PROMIS8a Pain Interference
Patient's perceived pain interference level on a scale of 8-40, per PROMIS Pain Interference Adult Form
Opioid Use after Surgery
Mean daily opioid use after surgery measured in milligram morphine equivalents (MME)

Full Information

First Posted
February 14, 2022
Last Updated
March 22, 2023
Sponsor
The Methodist Hospital Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05276258
Brief Title
Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients
Official Title
A Randomized Controlled Trial of cryoSPHERE (CRYOS/CRYOS-L) Ablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients Undergoing Robotic-Assisted Thoracoscopic Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
March 15, 2025 (Anticipated)
Study Completion Date
September 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Methodist Hospital Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective study is to compare the use of the cryoSPHERE probe to the standard-of-care method for pain management of patients receiving robotic-assisted thoracoscopic surgery, including reductions in opioid pain medication use and the development of post-surgical morbidity.
Detailed Description
Patients who take more opioid medications after surgery tend to have longer hospital stays, and they are at risk of developing pneumonia and other postoperative morbidities. Opioid-tolerant patients are at a higher risk of developing these morbidities because they often require higher doses of opioid medications to manage their post-operative pain. Reducing post-operative pain in these patients through non-opioid means helps reduce their risk of developing morbidities, and is potentially a more effective form of pain management, particularly in this patient population. This is a single-center, prospective cohort registry with a historical control, and an estimated duration of 2 years. This study's primary objective is to evaluate the cryoSPHERE probe for ablation in pain control after surgery (measured using opioid medication). The secondary objectives are the evaluation of morbidities, length of stay, cost, and incidence of neuroma formation. We plan to recruit 75 patients who will receive the cryoSPHERE probe and compare them to 75 patients who did not receive the cryoSPHERE probe. The experimental group will receive cryoSPHERE ablation of intercostal nerves and liposomal bupivacaine. The historical control group will have had robotic-assisted thoracoscopic surgery and an intercostal nerve block with liposomal bupivacaine and no cyroSPHERE probe.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Pain, Postoperative
Keywords
pain management, pulmonary surgical procedures, robotic surgical procedures, pneumonectomy, nerve block, neuroma, analgesics, opioid, bupivacaine, length of stay, drug tolerance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation
Arm Type
Experimental
Arm Description
The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
Arm Title
Historical Controls
Arm Type
Other
Arm Description
A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.
Intervention Type
Device
Intervention Name(s)
cryoSPHERE Ablation
Other Intervention Name(s)
cryoSPHERE
Intervention Description
The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
liposomal bupivacaine, Exparel
Intervention Description
A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
Primary Outcome Measure Information:
Title
Opioid Use Within 24 Hours After Chest Tube Removal
Description
Opioid use measured as the daily dose of milligram morphine equivalents (MME)
Time Frame
From the time of chest tube removal to 24 hours after chest tube removal
Secondary Outcome Measure Information:
Title
Total Emergent Adverse Effects (TEAE)
Description
Morbidity, defined as total emergent adverse effects (TEAE) for the experimental group vs. control
Time Frame
Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Title
Length of Hospital Stay
Description
Time spent in the hospital from admission for surgery until discharge or death
Time Frame
From admission to discharge or death, up to 1 year after surgery
Title
Mean Cost of Hospital Care
Description
Total cost of billed medical care for the surgery
Time Frame
From admission to discharge or death, up to 1 year after surgery
Title
Number of Readmissions
Description
The number of readmissions to the hospital
Time Frame
From initial admission for surgery to 28 days after surgery
Title
Neuroma Formation
Description
The formation of a neuroma around the site of nerve block administration
Time Frame
Time of discharge (up to 1 year after surgery), 3 months after surgery, and 6 months after surgery
Title
Pain Score
Description
Patient's perceived pain level on a scale of 1 to 10
Time Frame
Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Title
PROMIS3a Pain Intensity
Description
Patient's perceived pain level on a scale of 3-15, per PROMIS Pain Intensity Short Form 3a v1.0
Time Frame
Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Title
PROMIS8a Pain Interference
Description
Patient's perceived pain interference level on a scale of 8-40, per PROMIS Pain Interference Adult Form
Time Frame
Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery
Title
Opioid Use after Surgery
Description
Mean daily opioid use after surgery measured in milligram morphine equivalents (MME)
Time Frame
Day 1 after surgery, day 3 after surgery, 5 weeks after surgery, 3 months after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients 18-90 years of age Diagnosis requiring robotic-assisted thoracoscopic surgery Daily opioid use for at least 30 days consecutively at any point during the last 12 months prior to surgery or using opioids at the time of study enrollment Experimental group only: agreement and consent to comply with all aspects of the study protocol and data collection, including follow-up contact. Exclusion Criteria: Previous major surgery at the operative site (thoracotomy) Allergy to aluminum Allergy to plastics Allergy to bupivacaine Shingles disease Demyelinating illnesses Involvement with other interventional studies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Min Kim, MD
Organizational Affiliation
The Methodist Hospital Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Houston Methodist Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29708130
Citation
Goto T. What is the best pain control after thoracic surgery? J Thorac Dis. 2018 Mar;10(3):1335-1338. doi: 10.21037/jtd.2018.03.63. No abstract available.
Results Reference
background
PubMed Identifier
25912739
Citation
Rice DC, Cata JP, Mena GE, Rodriguez-Restrepo A, Correa AM, Mehran RJ. Posterior Intercostal Nerve Block With Liposomal Bupivacaine: An Alternative to Thoracic Epidural Analgesia. Ann Thorac Surg. 2015 Jun;99(6):1953-60. doi: 10.1016/j.athoracsur.2015.02.074. Epub 2015 Apr 23.
Results Reference
background
PubMed Identifier
32038918
Citation
Nobel TB, Adusumilli PS, Molena D. Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery. Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S373-S377. doi: 10.21037/tlcr.2019.05.14. No abstract available.
Results Reference
background
PubMed Identifier
32142814
Citation
Brown LM, Kratz A, Verba S, Tancredi D, Clauw DJ, Palmieri T, Williams D. Pain and Opioid Use After Thoracic Surgery: Where We Are and Where We Need To Go. Ann Thorac Surg. 2020 Jun;109(6):1638-1645. doi: 10.1016/j.athoracsur.2020.01.056. Epub 2020 Mar 3.
Results Reference
background
PubMed Identifier
29607171
Citation
Kim MP, Chan EY, Meisenbach LM, Dumitru R, Brown JK, Masud FN. Enhanced recovery after thoracic surgery reduces discharge on highly dependent narcotics. J Thorac Dis. 2018 Feb;10(2):984-990. doi: 10.21037/jtd.2018.01.99.
Results Reference
background
Citation
AtriCure, I., croSPHERE Probe Package Insert.
Results Reference
background
PubMed Identifier
30935731
Citation
Graves CE, Moyer J, Zobel MJ, Mora R, Smith D, O'Day M, Padilla BE. Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial. J Pediatr Surg. 2019 Nov;54(11):2250-2256. doi: 10.1016/j.jpedsurg.2019.02.057. Epub 2019 Mar 17.
Results Reference
background

Learn more about this trial

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

We'll reach out to this number within 24 hrs